vs
Side-by-side financial comparison of DIVERSIFIED HEALTHCARE TRUST (DHC) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $379.6M, roughly 1.9× DIVERSIFIED HEALTHCARE TRUST). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -5.6%, a 24.7% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -0.0%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-166.4M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 1.2%).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
DHC vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $379.6M | $708.5M |
| Net Profit | $-21.2M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | -12.6% | 21.6% |
| Net Margin | -5.6% | 19.1% |
| Revenue YoY | -0.0% | 32.0% |
| Net Profit YoY | 75.7% | 15.5% |
| EPS (diluted) | $-0.09 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $379.6M | $708.5M | ||
| Q3 25 | $388.7M | $659.9M | ||
| Q2 25 | $382.7M | $603.3M | ||
| Q1 25 | $386.9M | $558.6M | ||
| Q4 24 | $379.6M | $536.6M | ||
| Q3 24 | $373.6M | $533.3M | ||
| Q2 24 | $371.4M | $528.1M | ||
| Q1 24 | $370.8M | $511.0M |
| Q4 25 | $-21.2M | $135.1M | ||
| Q3 25 | $-164.0M | $111.1M | ||
| Q2 25 | $-91.6M | $90.3M | ||
| Q1 25 | $-9.0M | $114.6M | ||
| Q4 24 | $-87.4M | $117.0M | ||
| Q3 24 | $-98.7M | $96.4M | ||
| Q2 24 | $-97.9M | $88.4M | ||
| Q1 24 | $-86.3M | $102.6M |
| Q4 25 | -12.6% | 21.6% | ||
| Q3 25 | -43.4% | 21.5% | ||
| Q2 25 | -24.5% | 20.9% | ||
| Q1 25 | -2.7% | 20.3% | ||
| Q4 24 | -26.1% | 23.4% | ||
| Q3 24 | -26.5% | 21.1% | ||
| Q2 24 | -23.0% | 19.9% | ||
| Q1 24 | -23.7% | 20.4% |
| Q4 25 | -5.6% | 19.1% | ||
| Q3 25 | -42.2% | 16.8% | ||
| Q2 25 | -23.9% | 15.0% | ||
| Q1 25 | -2.3% | 20.5% | ||
| Q4 24 | -23.0% | 21.8% | ||
| Q3 24 | -26.4% | 18.1% | ||
| Q2 24 | -26.3% | 16.7% | ||
| Q1 24 | -23.3% | 20.1% |
| Q4 25 | $-0.09 | $4.65 | ||
| Q3 25 | $-0.68 | $3.86 | ||
| Q2 25 | $-0.38 | $3.10 | ||
| Q1 25 | $-0.04 | $3.67 | ||
| Q4 24 | $-0.37 | $3.67 | ||
| Q3 24 | $-0.41 | $3.01 | ||
| Q2 24 | $-0.41 | $2.75 | ||
| Q1 24 | $-0.36 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $105.4M | $497.0M |
| Total DebtLower is stronger | $2.4B | — |
| Stockholders' EquityBook value | $1.7B | $459.1M |
| Total Assets | $4.4B | $2.0B |
| Debt / EquityLower = less leverage | 1.47× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $105.4M | $497.0M | ||
| Q3 25 | $201.4M | $285.4M | ||
| Q2 25 | $141.8M | $46.3M | ||
| Q1 25 | $302.6M | $441.4M | ||
| Q4 24 | $144.6M | $669.4M | ||
| Q3 24 | $256.5M | $656.9M | ||
| Q2 24 | $265.6M | $510.9M | ||
| Q1 24 | $207.1M | $407.0M |
| Q4 25 | $2.4B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $3.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.7B | $459.1M | ||
| Q3 25 | $1.7B | $293.6M | ||
| Q2 25 | $1.9B | $172.4M | ||
| Q1 25 | $1.9B | $593.6M | ||
| Q4 24 | $2.0B | $825.5M | ||
| Q3 24 | $2.0B | $881.4M | ||
| Q2 24 | $2.1B | $763.6M | ||
| Q1 24 | $2.2B | $671.5M |
| Q4 25 | $4.4B | $2.0B | ||
| Q3 25 | $4.7B | $1.8B | ||
| Q2 25 | $4.8B | $1.6B | ||
| Q1 25 | $5.0B | $1.9B | ||
| Q4 24 | $5.1B | $2.1B | ||
| Q3 24 | $5.3B | $2.1B | ||
| Q2 24 | $5.3B | $1.9B | ||
| Q1 24 | $5.3B | $1.8B |
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.6M | $192.7M |
| Free Cash FlowOCF − Capex | $-166.4M | $188.1M |
| FCF MarginFCF / Revenue | -43.8% | 26.6% |
| Capex IntensityCapex / Revenue | 38.7% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $-280.3M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-19.6M | $192.7M | ||
| Q3 25 | $-49.3M | $246.2M | ||
| Q2 25 | $53.0M | $148.5M | ||
| Q1 25 | $-3.2M | $125.8M | ||
| Q4 24 | $112.2M | $190.7M | ||
| Q3 24 | $21.1M | $149.1M | ||
| Q2 24 | $44.3M | $116.4M | ||
| Q1 24 | $28.6M | $152.7M |
| Q4 25 | $-166.4M | $188.1M | ||
| Q3 25 | $-89.8M | $235.5M | ||
| Q2 25 | $18.8M | $142.4M | ||
| Q1 25 | $-42.9M | $115.8M | ||
| Q4 24 | $-89.5M | $183.0M | ||
| Q3 24 | $-26.1M | $138.5M | ||
| Q2 24 | $3.3M | $103.5M | ||
| Q1 24 | $-18.1M | $147.2M |
| Q4 25 | -43.8% | 26.6% | ||
| Q3 25 | -23.1% | 35.7% | ||
| Q2 25 | 4.9% | 23.6% | ||
| Q1 25 | -11.1% | 20.7% | ||
| Q4 24 | -23.6% | 34.1% | ||
| Q3 24 | -7.0% | 26.0% | ||
| Q2 24 | 0.9% | 19.6% | ||
| Q1 24 | -4.9% | 28.8% |
| Q4 25 | 38.7% | 0.6% | ||
| Q3 25 | 10.4% | 1.6% | ||
| Q2 25 | 8.9% | 1.0% | ||
| Q1 25 | 10.2% | 1.8% | ||
| Q4 24 | 53.1% | 1.4% | ||
| Q3 24 | 12.6% | 2.0% | ||
| Q2 24 | 11.0% | 2.4% | ||
| Q1 24 | 12.6% | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DHC
| Senior Housing Operating Portfolio Segment | $323.4M | 85% |
| Rental Income | $56.2M | 15% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
